Novel blood‐based proteomic signatures across multiple neurodegenerative diseases
Alzheimer's & Dementia · 2025-03 · 21 (3)
DOI: 10.1002/alz.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 27.03.2025. Verfasst von Robert Durcan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences, University of Cambridge and Cambridge University Hospitals NHS Trust, Cambridge, UK. Hauptthemen laut MEDLINE: Proteomics, Neurodegenerative Diseases, Alzheimer Disease. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PSP Association, Swedish Research Council, Cambridge University Centre for Parkinson-Plus.
Abstract (Originalsprache)
INTRODUCTION Blood‐based biomarkers have the potential to support early and accurate diagnoses of neurodegenerative diseases, which are sensitive to molecular pathology and are predictive of outcome. We evaluated a novel multiplex proteomic method in people with diverse neurodegenerative diseases. METHODS Serum from people with Alzheimer's disease ( N = 36), Lewy body dementia ( N = 34), frontotemporal dementia ( N = 36), and progressive supranuclear palsy ( N = 36) and age‐matched controls ( N = 30) was analyzed with the nucleic acid linked immuno‐sandwich assay (NULISA) central nervous system panel (≈ 120 analytes) and inflammation panel (250 analytes). Biomarkers were compared across groups and included as predictors of survival. RESULTS The NULISA panels demonstrated high sensitivity and reliability for detecting multiple biomarkers across neurodegenerative disorders. There were condition‐specific proteomic biomarkers, while neurofilament light chain, corticotropin‐releasing hormone, CD276, and a data‐driven inflammation pattern were significant transdiagnostic outcome predictors. DISCUSSION The sensitive NULISA multiplex approach supports differential diagnosis and target identification, with prognostically informative dementia‐related biomarkers. Highlights We tested the novel technology nucleic acid linked immuno‐sandwich assay (NULISA) in people with diverse neurodegenerative diseases, which demonstrated high sensitivity and reliability for detecting multiple biomarkers in serum samples. We compared the NULISA central nervous system serum results to single molecule array (Simoa) plasma assays for phosphorylated tau (p‐tau)217, p‐tau231, neurofilament light chain (NfL), and glial fibrillary acidic protein, finding strong correlations. Increased levels of serum NfL were identified across all patient groups and most elevated in the frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP) cohorts, while p‐tau epitopes were the most significant markers in patients with Alzheimer's disease (AD) and Lewy body dementia. Patients with FTD and PSP showed upregulation of many inflammation markers, compared to controls and patients with AD. We found condition‐specific proteomic biomarkers, while NfL, corticotropin‐releasing hormone, CD276, and data‐driven immune signatures were significant transdiagnostic predictors of clinical outcomes (survival rates).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neurosciences, University of Cambridge and Cambridge University Hospitals NHS Trust, Cambridge, UK.
- UK Dementia Research Institute, University College London, London, UK.
- Department of Psychiatry, University of Cambridge, Cambridge, UK.
- UK Dementia Research Institute, University of Cambridge, Cambridge, UK.
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
- Banner Alzheimer's Institute, University of Arizona, Phoenix, Arizona, USA.
Förderung
- PSP Association
- Swedish Research Council
- Cambridge University Centre for Parkinson-Plus
- The Galen and Hilary Weston Foundation
- Swedish State Support for Clinical Research
- Wellcome Trust
- UK Dementia Research Institute
- NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Durcan, R., Heslegrave, A., Swann, P., Goddard, J., Chouliaras, L., Murley, A. G., Savulich, G., Bevan-Jones, W. R., Swann, O., Ashton, N. J., Blennow, K., McEwan, W., Zetterberg, H., Rowe, J. B., O'Brien, J. T., & Malpetti, M. (2025). Novel blood‐based proteomic signatures across multiple neurodegenerative diseases. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.70116
Vancouver
Durcan R, Heslegrave A, Swann P, Goddard J, Chouliaras L, Murley AG, et al. Novel blood‐based proteomic signatures across multiple neurodegenerative diseases. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.70116
BibTeX
@article{Durcan2025,
author = {Durcan, Robert and Heslegrave, Amanda and Swann, Peter and Goddard, Julia and Chouliaras, Leonidas and Murley, Alexander G and Savulich, George and Bevan-Jones, W Richard and Swann, Owen and Ashton, Nicholas J and Blennow, Kaj and McEwan, William and Zetterberg, Henrik and Rowe, James B and O'Brien, John T and Malpetti, Maura},
title = {Novel blood‐based proteomic signatures across multiple neurodegenerative diseases},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {3},
doi = {10.1002/alz.70116}
}
EUVIMED